Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Zawartość zarchiwizowana w dniu 2024-05-27

Development of prophylactic and therapeutic vaccines optimised for cellular processing and presentation to t lymphocytes and targeted to professional antigen presenting cells (protarvac)

Cel

Vaccines eliciting T cell immunity are likely to be important for protection against diseases such as infection by HIV, HCV or malaria parasites. Current concepts of peptide or protein fragment vaccination do not consider intracellular antigen processing in epitome selection and design of poly-epitome strings. We propose to study proteolysis by immune- and housekeeping protease, and bylysosomal proteases, so as to identify novel epitomes by an enhanced "reverse immunology" approach, to determine distinct epitome sets suitable for preventive and therapeutic vaccines, and to design linkers for optimal intracellular epitoperelease and transport. T cell vaccines for HIV, HCV and malaria will be designed and tested with healthy donor or patient lymphocytes and in a marine malaria model.

Zaproszenie do składania wniosków

Data not available

System finansowania

CSC - Cost-sharing contracts

Koordynator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Wkład UE
Brak danych
Adres
161,Rue de SFvres 161
75743 PARIS
Francja

Zobacz na mapie

Koszt całkowity
Brak danych

Uczestnicy (3)